Doxorubicin, bleomycin, vinblastine, and dacarbazine combination chemotherapy used for the treatment of patients with Hodgkin lymphoma.
ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is the most widely used regimen for the treatment of early and advanced stage Hodgkin lymphoma (HL). Treatment of patients with early stage classical HL evolved over the last three decades. Radiation therapy alone as the single treatment modality is no longer practiced. Today, the most widely used approach is combined modality therapy (chemotherapy plus involved field radiation therapy). In general, two (for favorable early stage) to four (for unfavorable early stage) cycles of ABVD plus 30 Gy of involved field radiation therapy is the most widely used standard of care approach. Using this approach, more than 90% of the patients are expected to be cured of their disease. Patients with bulky stage II disease, (especially with bulky mediastinal mass), or stage II with...
- 2.Meyer RM, Gospodarowicz MK, Connors JM et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634–4642PubMedCrossRefGoogle Scholar
- 3.Straus DJ, Portlock CS, Qin J et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489PubMedCrossRefGoogle Scholar